A Study of Plasma Fibrinogen Levels in Stroke by Balachandar, S
 
 
A STUDY OF PLASMA FIBRINOGEN LEVELS IN 
STROKE 
Dissertation submitted to 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY 
CHENNAI- TAMILNADU 
 
 
 
In partial fulfillment for the Degree of 
DOCTOR OF MEDICINE 
BRANCH I –M.D., (General Medicine) 
APRIL-2015 
 
DEPARTMENT OF MEDICINE 
TIRUNELVELI MEDICAL COLLEGE 
TIRUNELVELI- 627011 
TAMILNADU 
 
 
 
CERTIFICATE 
 
    This is to certify that the Dissertation entitled “A STUDY OF 
PLASMA FIBRINOGEN LEVELS IN STROKE” is a bonafide original 
work of Dr.S.BALACHANDAR, in partial fulfillment of the requirement for 
M.D., BRANCH- I General Medicine Examination of The Tamilnadu 
Dr.M.G.R. Medical university, Chennai to be held in April 2015 
The bonafide work is carried out by him under my guidance and 
supervision. This dissertation partially or fully has not been submitted for 
any other degree or diploma of this university or other. 
 
 
Prof.Dr.A.S.Mohan MD                Prof.Dr.M.R.Vairamuthuraju  MD 
Unit Chief, Unit II                                Professor and HOD, 
Department of Medicine,                    Department of Medicine 
Tirunelveli Medical College,                Tirunelveli Medical College, 
Tirunelveli – 627011.   Tirunelveli – 627011. 
 
 
 
THE DEAN, 
TIRUNELVELI MEDICAL COLLEGE & HOSPITAL 
TIRUNELVELI – 627011. 
 
 
 
 
DECLARATION 
 
 
 
 
      I, Dr. S.BALACHANDAR, solemnly declare that, I carried out this 
work on “A STUDY OF PLASMA FIBRINOGEN LEVELS IN 
STROKE” at, Department of General medicine, Tirunelveli Medical 
College and Hospital during the period of August 2013 to August 2014. 
           I also declare that this bonafide work or a part of this work was not 
submitted by me or any others for any award, degree, diploma to any 
university, found either in India or abroad. 
This is submitted to The Tamilnadu Dr.M.G.R.Medical University, 
Chennai, in partial fulfillment of the rules and regulations for the MD 
Degree Branch I General Medicine Examination, to be held on April 2015. 
 
 
 
 
Place : TIRUNELVELI    
 
 
 
 
 
DR.S.BALACHANDAR , 
POST GRADUATE, 
M.D. GENERAL MEDICINE 
TIRUNELVELI MEDICAL 
COLLEGE 
 
 
 
ACKNOWLEDGEMENT 
 
         I am greatly indebted to my unit chief and guide 
Prof.DR.A.S.MOHAN MD, who inspired, encouraged and guided me in 
every step of this study. 
        I express my heartfelt gratitude to the Professor and Head of the 
Department of medicine  Prof.Dr.M.R.VAIRAMUTHURAJU MD, for his 
valuable support and guidance in preparing this dissertation. 
       I sincerely thank our Dean Dr.L.D. THULASIRAM. MS ORTHO, 
who permitted me to carry out this study in Tirunelveli Medical College 
Hospital. 
        I am thankful to all my senior Assistant Professors 
DR.PERIYASAMY M.D, DR.RAJESH MD, DR.MARCHWIN 
KINGSTON SAMUEL MD for their valuable suggestions and help given for 
my study. 
      I also thank the Department of Biochemistry and Radiology for their 
help in investigation aspects.  
I am deeply indebted to my parents and my wife whose constant 
encouragement and support helped me to complete this dissertation.. 
I sincerely thank all the patients who cooperated with me for 
participating in the study. 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
S.NO                        TITLE PAGE NO 
1. INTRODUCTION 1 
2. AIMS & OBJECTIVES 4 
3. REVIEW OF LITERATURE 5 
4. MATERIALS AND METHODS 59 
5. OBSERVATIONS AND RESULTS 68 
6. CHARTS AND GRAPHS 77 
7. DISCUSSION 101 
8. CONCLUSION 104 
9. FUTURE DIRECTIONS 105 
10. BIBLIOGRAPHY  
 
ANNEXURES 
I. PROFORMA 
II. MASTER CHART 
III. ABBREVIATIONS     
 
 
 
 
 
A STUDY OF PLASMA FIBRINOGEN LEVELS IN STROKE 
ABSTRACT 
INTRODUCTION 
              Increased plasma fibrinogen is a risk factor for vascular diseases 
related to atherosclerosis. Its predictive value in stroke is not well established. 
We conducted this study to establish the significance of hyperfibrinogenemia 
with severity and functional outcome of acute stroke. 
METHODS  
              We studied 100 patients who got admitted with stroke within 24 hours 
of symptom onset. We noted the history regarding risk factors and assessed the 
severity of stroke by Scandinavian stroke scale and functional outcome of 
stroke by modified Rankin scale at the time of admission and discharge.  Plasma 
fibrinogen was measured in all patients. The values computed and analysed with 
pearson correlation and chi-square tests. 
RESULTS 
            The mean fibrinogen was 405.6 mg/dl. The mean value was increased in 
patients having ischemic stroke. Patients having hyperfibrinogenemia at the 
time of admission has increased severity of stroke (p<0.01) as assessed by 
Scandinavian stroke scale (mean-29.91) and similarly has poor functional 
outcome as evidenced by increased scores of modified Rankin scale (p<0.01) at 
the time of admission and discharge.12 patients were expired during the course 
of stay in hospital. The mean fibrinogen among the dead patients was 
significantly higher (439.58) as compared to overall mean fibrinogen value. 
Among the risk factors, although the mean value was increased in smokers, 
hypertension and diabetes, we could establish a significant relation only with 
diabetes. 
CONCLUSION 
             Increased plasma fibrinogen shortly after ischemic stroke predicts the 
severity and poor functional outcome of stroke. 
Key words: fibrinogen, stroke severity, Scandinavian stroke scale, modified 
Rankin scale. 
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INTRODUCTION 
      Stroke is a common neurological illness causing significant morbidity 
and mortality among all hospital admissions in both developing and 
developed countries. The prevalence of stroke in India ranges from 84 to 262 
per lakh in rural areas and 334 to 424 in urban areas .The case fatality rate is 
highest in Kolkata which corresponds to 42%. In urban India stroke accounts 
for 1% mortality of all hospital admissions, 4% in all medical cases and 
about 20% in all disorders of central nervous system 
[1]
.   
    Important Risk factor for stroke includes Diabetes, Hypertension, 
smoking and dyslipidemia.
 
      Fibrinogen is a soluble plasma glycoprotein that consists of three non-
identical pairs of polypeptide chains Aα, Bβ and γ chains [2]. 
In the first phase of thrombus formation, thrombin converts soluble 
fibrinogen into insoluble fibrin. Thrombin cleaves Aα and Bβ chains thereby 
releasing fibrinopeptides . These fibrinopeptides initiate a process in which 
fibrin monomers begin to gel. These fibrin monomers polymerise to form 
fibrin polymers. This process continues and elongation of polymers causes 
formation of protofibrils. Once a critical 
[1]
 mass of long protofibrils is 
established, the protofibrils form lateral contacts with other protofibrils 
thereby forming fibrin clot. Fibrin clot thereby potentiates formation of 
thrombosis. 
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        Epidemiological observations indicate that high plasma fibrinogen 
levels strongly correlate with two major thrombotic complications of 
atherosclerosis, stroke and myocardial infarction. Thrombosis is increasingly 
recognized as a central mechanism in stroke as well as in myocardial 
infarction. Fibrinogen is involved in events thought to play a major role in 
thrombosis 
[3]
. 
At the beginning of stroke the elevated level of inflammatory markers 
such as C-reactive protein (CRP) or fibrinogen may reflect the underlying 
burden of atherosclerosis and/or the association of concomitant risk factors 
(e.g. Diabetes mellitus, Hypertension, Obesity)
[4].
 In addition, the blood level 
of these markers could rise during stroke as a part of the acute phase reaction 
[1] 
. 
There is a significant inter individual variability in inflammatory 
response after stroke. In Scottish heart health study it was found that plasma 
fibrinogen level was elevated in smokers, premature heart disease, known 
hypertensive patients, Diabetics and patients with intermittent claudication. 
     In another study it was found that sustained increase in fibrinogen 
value during an acute stroke episode predicts the worse outcome irrespective 
of the baseline fibrinogen value. In this study, the fibrinogen was measured 
at day 1,7, and 14 and compared with stoke outcome scales NIHSS (National 
Institute of Health Stroke Scale) and Modified Rankin Scale.  
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      The relationship between fibrinogen and thrombosis may strengthen 
the predictive value of this protein and suggest new treatment in 
management of stroke. It remains uncertain whether this rise in 
inflammatory marker is an epiphenomenon to stroke severity or it 
contributes independently to functional stroke outcome. 
     Many case control studies done previously proven that plasma 
fibrinogen levels was elevated in smokers, hypertensives and dyslipidemia 
patients. 
     Hence this study is designed to investigate mainly the association 
between plasma fibrinogen levels and acute stroke outcome 
[5] 
. 
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AIMS AND OBJECTIVES 
 
1. To study plasma fibrinogen levels in patients with stroke. 
2. To correlate fibrinogen level with other major risk factors for stroke. 
3. To find out immediate prognosis of patients (during hospital stay) with 
stroke who have abnormal fibrinogen level. 
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REVIEW OF LITERATURE 
   The brain receives a constant supply of glucose and oxygen from the 
blood for its normal functioning. The blood perfuses at a rate of 55 to 70 ml 
per 100 g of brain tissue per minute. The principal source of energy for this 
brain tissue is derived exclusively from oxidation of glucose. If the blood 
perfusion is reduced below 15 ml per 100 g per minute , ischemia develops 
due to hypoxia and when it is prolonged , it will lead on to death of neurons 
and glia. 
   “Stroke” is defined as an acute neuronal injury that occurs as a result 
of diseases of cerebral vasculature and its contents 
[6]
.The severity of stroke 
varies from complete recovery over a few days to persistent disability or 
death. 
Transient ischemic attack (TIA) is defined as a transient episode of 
neurologic deficit caused by brain, spinal cord, or retinal ischemia, which 
recovers within 24 hours of duration
[7]
. During a 5 year follow up of this TIA 
patients 30% of these patients are more prone to develop a full-fledged 
stroke. 
“RIND” (Reversible ischaemic neurological deficit) refers to the 
resolution of symptoms within a period of seven days.  
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Approximately 80 percentage of strokes are due to ischaemic cerebral 
infarction and 20 percentage are due to brain haemorrhage. Stroke is the 3
rd
 
most common cause of death in developed nations. In India the prevalence 
rate is in the range of 200 per 1 lakh persons. 
Historical Review  
     Hippocrates was probably the first to write about the medical aspects 
of stroke. 
      Hippocrates wrote in his aphorisms on apoplexy, 
“Persons are most subject to apoplexy between the ages of forty and 
sixty”, and attacks of numbness might reflect “impending apoplexy”. 
    A few hundred years after Hippocrates, Galen (131-201 AD) 
described the anatomy of the brain and its blood vessels from dissections of 
animals. 
    During the last half of the seventeenth century, two important 
physicians Johann Jakob Wepfer and Thomas Willis made important 
contributions to understand the anatomy of blood circulation and clinical 
features of stroke. 
Wepfer was the first to show clearly that bleeding into the brain was 
an important cause of apoplexy.  
    Thomas Willis, a Neuroanatomist best known for his CEREBRI 
ANATOME, which contained a description of a circle of anastomotic 
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vessels at the base of the brain. Willis recognized transient ischemic attacks 
and the phenomenon of embolism, as well as existence of occlusion of the 
carotid artery. 
         During the eighteenth century, one of the giants in medical history, 
Giovanni Battista Morgagni (1682-1771) was able to focus attention on 
pathology and the
[8] 
cause of disease. Morgagni also described cases of 
intracerebral haemorrhage and recognized that paralysis was on the side of 
the body opposite to the brain lesion. 
     John Abercrombie contributed a more detailed clinical classification 
of apoplexy in his general text published in 1828. Abercrombie used the 
presence of headache, stupor, paralysis and outcome to separate apopletics 
into three clinical groups. 
    Detailed observation of the distribution of the arteries and veins in the 
cranium were made by Duret a French neurosurgeon, by Stopford in Britain 
and later by Foix. 
   During the twentieth century, especially in the 1970’s and 1980’s, 
there was an explosive growth in knowledge about stroke. Advances in 
technology allowed better visualization of the anatomy and the functional 
aspects of the brain and of vascular lesions during life.  
    The technological revolution probably began with the work of the 
Portuguese neurosurgeon Moniz (1874-1955). Moniz surgically exposed and 
temporarily 
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ligated the internal carotid artery in the neck and then injected by hand a 
30% solution of sodium iodide, taking skull films later at regular intervals.           
Hounsfield of the research laboratories of Electrical musical instruments in
 
Britain originated the concept of computed tomography (CT) during the mid 
1960’s.  
   The instrument was first tried at the Atkinson-Morley hospital in 
London. CT Scanners were first introduced to North America in 1973. Films 
from first generation scanners were quite primitive, but by the late 
1970’sthird generation scanners had made CT a useful, almost indispensable, 
diagnostic tool. 
CT allowed clear distinction between the brain ischemia and 
haemorrhage and allowed definition of the size and location of most brain 
infarcts and haemorrhages. 
    The advent of Magnetic Resonance Imaging (MRI) in clinical 
medicine in the mid 1980’s was a further major advance. MRI proved 
superior to CT in showing old hemosiderin containing haemorrhages and in 
imaging vascular malformations, lesions abutting on bony surfaces, and 
posterior fossa structures. 
    Ultrasound was introduced to medicine in 1961 by Franklin and 
colleagues. 
B Mode Ultrasound was soon used to provide images of the extra 
cranial carotid arteries non-invasively. 
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    In 1982, Aaslid and colleagues introduced a high energy bidirectional 
pulsed Doppler system that used low frequencies to study intracranial 
arteries, termed Transcranial Doppler ultrasound (TCD). TCD made possible 
the non-invasive detection of severe occlusive disease in the major 
intracranial arteries during life as well as sequential study of these lesions. 
    Introduction of Echocardiography and ambulatory cardiac rhythm 
monitoring in the 1970’s and 1980’s greatly improved cardiac diagnoses and 
detection of cardiac sources of embolism. 
    By the end of twentieth century, advanced brain imaging with CT, 
MRI, and newer MR modalities, diffusion, perfusion and functional MRI, 
MR Spectroscopy, were able to show clinicians the localization, severity and 
potential reversibility of brain ischemia. Vascular lesions could be quickly 
and safely defined using spiral CT angiography, MR angiography, 
extracranial and transcranial ultrasound. 
STROKE 
 Stroke can be broadly classified into two types: 
 Ischemic stroke.  
 Haemorrhagic stroke.  
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This type of stroke occurs due to occlusion of the arteries supplying 
brain either by thrombosis or embolism. This results in decreased perfusion 
to the affected brain tissue thereby causing cell death. 
Causes of ischemic stroke 
Thrombosis 
 Small / large vessel disease 
 Dehydration 
Embolism 
 Atrial fibrillation  
 Paradoxical emboli 
 Artery to artery embolism 
 Dilated cardiomyopathy 
 Left atrial myxoma/ thrombus 
 Valvular pathology 
 Ischemic heart disease 
 Valvular vegetations 
 Inter atrial septal aneurysm 
Rare causes 
 Coagulation factor deficiency like protein C,S 
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 OCP use 
 Antiphospholipid antibody syndrome 
 Cancer associated 
 Pregnancy 
 Polycythemia vera 
 Inflammatory bowel disease 
 Fibro muscular dysplasia 
 MoyaMoya disease 
 Nephrotic syndrome 
 Leukoaraiosis 
 Trauma to vessel 
 Irradiation 
 Migraine 
 Systemic lupus erythematoses 
 Post-operative period 
 Snake bite 
 Hanging 
 Vasculitis 
 Disseminated intravascular coagulation  
Causes of Intracerebral haemorrhage 
 Systemic hypertension 
12 
 
 Trauma 
 Haemorrhagic transformation of old infarct 
 Bleeding in space occupying lesion 
 Bleeding diathesis 
 Aneurysmal rupture 
 AV malformations 
 Cerebral amyloid angiopathy 
 Telangiectasis 
 Post thrombolysis 
 Use of anticoagulants 
 Renal failure 
 Thrombotic Thrombocytopenic Purpura 
 Tumours  
 Drug abuse 
 Snake bite 
 Thrombocytopenia 
 Antiplatelets 
 Cortical vein thrombosis 
 Liver cell failure 
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PATHOPHYSIOLOGY OF STROKE 
CEREBRAL AUTOREGULATION   
Under normal circumstances, cerebral blood flow mainly depends 
upon the amount of vascular resistance within cerebral blood vessels, which 
is related to their diameter
[9]
. Dilatation of blood vessels leads to increased 
cerebral blood flow, whereas constriction of vessels has the opposite effect. 
Cerebral perfusion pressure also determines the cerebral blood flow. 
Cerebral autoregulation maintains the cerebral blood flow at a 
relatively constant rate despite 
[9-11]
 variations in perfusion pressure. The 
mechanism by which autoregulation occurs is not well understood, which 
may involve multiple pathways. There are evidences which suggest that the 
smooth muscle in cerebral vessels can respond directly to changes in 
perfusion pressure, contracting when pressure increases and relaxing when 
pressure decreases. Reductions in cerebral blood flow may lead to cerebral 
vasodilatation due to release of vasoactive substances, although the 
substance responsible for this has not been identified. Nitric oxide which 
released from vascular endothelium appears to play a role in autoregulation. 
Cerebral blood flow is maintained by autoregulation  which typically 
occurs within a range of 60 to 150 mmHg of mean arterial pressure. The 
upper and lower limits vary between individuals, However beyond this 
range, the brain is unable to compensate for changes in perfusion pressure, 
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and the cerebral blood flow increases or decreases passively with 
corresponding changes in pressure, resulting in the risk of ischemia at low 
pressures and edema at high pressures. 
FIGURE-1 
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CEREBRAL AUTOREGULATION DURING STROKE   
Cerebral auto regulation is impaired due to some disease conditions, 
which includes ischemic stroke also. When cerebral perfusion pressure 
decrease there will be cerebral vascular dilatation and when it falls below the 
compensatory capacity of the brain it will lead to decrease in the cerebral 
blood flow. Initially, the oxygen extraction fraction is increased in order to 
maintain levels of oxygen delivery to the brain. As the cerebral blood flow 
continues to fall, other mechanisms come into play. 
FIGURE-2 
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   In patient with hypertension autoregulation usually occurs at higher 
arterial pressures. Reduction of blood pressure to normal levels could 
actually exacerbate the derangement to autoregulation that occurs during 
stroke and lead to a further decrease in cerebral blood flow. 
CONSEQUENCES OF REDUCTION IN BLOOD FLOW DURING 
STROKE  
The human brain is very much sensitive to even a short duration of 
ischemia. Even though brain is only 2 to 3% of total body weight, the blood 
flow it receives is 20 to 25% of the total cardiac output. The brain has no 
energy stores of its own, and therefore it depends on the blood for their 
delivery. So even a brief deprivation can lead to death of the affected brain 
tissue. During stroke, reduction of blood flow to brain results in deprivation 
of glucose and oxygen. 
Commonly strokes are due to ischemia, which affects the small part of 
the brain mainly affecting a single blood vessel and its branches. Region 
which is commonly involved is the area supplied by the same vessel which is 
immediately surrounding the vessel. If the ischemia is prolonged in this area, 
cells will die by necrosis and the peripheral area which receives nutrients and 
oxygen by collateral vessel will not die immediately, which can be revived 
by timely intervention and restoration of blood flow. This area which 
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surrounds the dead cells is known as ischemic penumbra and the area 
underwent necrosis is known as infarct.  
MECHANISMS OF ISCHEMIC CELL INJURY AND DEATH   
A sequence of events occurs following brain ischemia leading to brain 
cell death. The possible mechanisms 
[12-13]
are  
1. ATP depletion 
2. Na+ ,K+ and Ca2+ ionic concentration changes 
3. Increase amount of lactic acid which leads to acidosis 
4. Oxygen free radicals 
5. Proteolytic enzymes  
6. Accumulation of water inside the cell 
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FIGURE-3 
 
    As a consequence of the electrical failure that occurs as a result of 
ischemia, there will be increased secretion of excitatory Neurotransmitter at 
the synapse will cause the glutamate 
[14]
 receptor activation and lead to out 
flow of the potassium and inflow of the sodium 
[15-18]
 and calcium ion. It will 
lead to variety of effects. The main subtypes of glutamate receptors involved 
are 
1.  N-methyl-D-aspartate (NMDA) receptor (main) 
2.  The alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid 
(AMPA) 
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3.  Metabotropic glutamate receptors. Activation of these receptors leads 
to membrane depolarization and increased calcium influx. 
  Another effect of NMDA receptor activation is the production of nitric 
oxide
[ 19 ]
. The activity of nitric oxide synthase (NOS) and the total amount 
of nitric oxide present in the brain are increased following exposure to 
hypoxia
[ 20 ]
. 
    Nitric oxide is an important signalling molecule within the body and 
can be beneficial at normal physiologic levels. As an example, endothelial 
nitric oxide synthase (eNOS) leads to the production of low levels of nitric 
oxide that cause vasodilation and increase blood flow
 [21]
. However, neuronal 
nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) 
result in larger amounts of nitric oxide that may lead to brain injury. Nitric 
oxide is a free radical and reacts directly with cellular components to damage 
them. Nitric oxide can also react with another free radical, Superoxide, to 
produce the highly reactive peroxynitrite. Peroxynitrite causes single strand 
breaks in DNA 
[22]
. This results in the activation of DNA repair enzymes, 
which consume vital energy needed for other processes. DNA damage also 
may activate the process of apoptosis, leading to cell death. 
The production of reactive oxygen species, a normal by product of 
oxidative metabolism, is also increased during ischemia. Like nitric oxide, 
they can react with and damage cellular components. Injury to the plasma 
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membrane of a cell can lead to inability to control ion flux, resulting in 
mitochondrial failure. Reactive oxygen species, as well as calcium influx and 
other factors, can also permeabilize the mitochondrial membrane 
[ 23 ]
.This 
leads to metabolic failure as well as release of initiators of apoptosis and 
DNA damage. Metabolic failure results in the depletion of cellular ATP 
levels. ATP is required for nuclear condensation and DNA degradation in the 
final stages of apoptosis 
[24]. In the absence of ATP, cell death occurs by 
necrosis rather than apoptosis. 
The release of by products from cellular damage and death by necrosis 
activates components of the inflammatory pathway 
[ 25 ]
. The role that 
inflammation plays during ischemia is mixed, having both positive and 
negative effects
[ 26 ]
. On way the surrounding inflammation results in 
proliferation of blood vessels and thereby increasing the blood flow to 
affected region, this will deliver more oxygen and glucose to the tissues. On 
the other hand, increased blood flow may also deliver more calcium to the 
area where the damage will be more. 
Inflammation also results in the migration of activated leukocytes to 
damaged tissues
[ 27]
. Although these leukocytes may remove damaged and 
necrotic tissues, they also release cytokines to attract additional 
inflammatory cells. Under severe inflammatory conditions, these cytokines 
can accumulate to toxic levels. 
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NECROSIS AND APOPTOSIS  
Cell death following cerebral ischemia or stroke can occur by two way 
either by necrosis or apoptosis. 
  The process of necrosis is not well understood. The changes include  
1) Condensation of chromatin  
2) Swelling of endoplasmic reticulum 
3) Ribosomal dispersion
[28]
 
  There will be swelling of the entire cell and plasma membrane and 
mitochondria after chromatin condensation. Eventually this cell leaks out the 
materials into the adjacent tissues and triggers the inflammation in the 
surrounding areas. 
    Apoptosis is nothing but a programmed cell death. Here also 
chromatin condensation takes place similar to necrosis in early stages. But in 
later stages the cell shrinks and the nucleus fragments into pieces and 
activates caspases and leads to destruction of the cell. This apoptosis is 
highly regulated by various enzymes like caspases and p53 gene.  
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There are three known pathways by which apoptosis can be initiated 
[ 29 ]
: 
 Mitochondrial permeabilization 
 Death receptor (Fas) pathway 
 Endoplasmic reticulum stress 
FIGURE-4 APOPTOSIS VS NECROSIS 
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    The most important pathway is permeabilization of the mitochondria 
and release of cytochrome C into the cytoplasm. Activation of membrane-
bound Fas, the so called "death receptor," and the accumulation of misfolded 
proteins at the endoplasmic reticulum during stress, can also lead to 
apoptosis. These initiators all lead to the activation of caspases that cleave 
cellular proteins and eventually cause cell death. Caspase independent 
mechanisms of apoptosis have also been proposed. 
The pattern of cell death after cerebral ischemia, as seen in animal 
models, depends on the nature of the insult to cerebral tissue 
[ 30 ]
. In global 
cerebral ischemia that occurs after cardiac arrest and resuscitation or 
transient severe systemic hypotension, the entire brain is exposed to 
ischemia. Formation of infarct is not immediate, but rather occurs after a 
delay of 12 hours to several days. Cell death is limited to those regions of the 
brain that are particularly susceptible to ischemic damage, such as the CA1 
and CA4 regions of the hippocampus, the striatum, and cortical layers two 
and five. Cell death in these regions occurs primarily by apoptosis. 
  Focal cerebral ischemia is a more common pattern than global 
ischemia in human stroke. In animal models of focal ischemia, changes in 
cell morphology are visible microscopically as early as two to three hours 
after the insult, and the infarct develops rapidly over a period of 6 to 24 
hours. Cell death occurs by necrosis in the core, with apoptotic cells located 
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at the periphery. In addition to the type of insult, the duration of ischemia 
also affects the pattern by which cell death occurs. Longer ischemic insults 
produce greater damage to cerebral tissue, resulting in an increased 
proportion of necrosis and decreased proportion of apoptosis. 
There have been few studies of apoptosis in the brain following stroke 
in human patients. However, accumulating evidence suggests that apoptosis 
is involved 
[31-34 ]
, as illustrated by the following observations: 
 In a neuropathology study that compared specimens from 27 patients 
who had cerebral infarction with specimens from rat brains subjected 
to experimental transient forebrain ischemia, the patterns of cell death 
were similar in human and animal brain tissue and included both 
morphologic and histochemical findings typical of apoptosis 
[31]
. In the 
human stroke specimens, apoptosis was apparent during the subacute 
stage, but was not seen in acute or chronic stages. 
 In another neuropathology report that compared 13 cases of fatal 
ischemic stroke with three patients who died of non-neurologic causes, 
histochemical and morphologic changes indicative of apoptosis were 
seen in cells throughout the brain of both patients and controls 
[ 34] .The 
morphologic changes were more advanced in the peri-infarct region 
and infarct core of the patients with stroke. Apoptotic cells were 
located primarily within the peri-infarct region, consisting of up to 
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26% of all cells. Increased ischemic damage and neuronal necrosis 
was associated with a decrease in the percentage of apoptotic cells. 
The deciding factor in determining whether cells undergo necrosis or 
apoptosis seems to be the level of energy available in the form of ATP, 
which is required for formation of the apoptosome. Apoptosis is unable to 
proceed in its absence. When energy levels are limiting, cell death occurs by 
necrosis rather than by apoptosis. The role of ATP in the mechanism of cell 
death has been investigated primarily using cell culture models. Cultured 
neurons depend on the presence of serum in the culture medium for survival. 
If the serum is removed, the cells die by necrosis. In serum-free media with 
added glucose, however, the cells die by apoptosis. 
ATP levels are decreased in acute stroke because of decreased blood 
supply. Glucose metabolism is decreased by about 50% in both global and 
focal ischemia models of stroke. As a consequence, ATP levels may fall to 
10% of normal in global models or 25% in the infarct core in focal ischemia 
models. ATP levels in the penumbra, however, only drop to 50% to 70% of 
normal 
[ 35 ]
. 
ATP levels in the brain may also be decreased by mitochondrial 
damage or failure, activity of DNA repair enzymes, such as PARP, and 
neuronal depolarization related to glutamate excitotoxicity. In stroke, in the 
central area of infarction where the ATP level is least, necrosis takes place 
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whereas in the penumbra ATP levels will be slightly more than the central 
area and thereby apoptosis occurs. Hence the duration of ischemia directly 
related to the area of necrosis. 
LOSS OF BRAIN STRUCTURAL INTEGRITY  
  Cerebral ischemia and infarction leads to loss of the structural 
integrity of the affected brain tissue and blood vessels. This process of tissue 
destruction and neurovascular disruption is mediated by the release of 
various proteases, like the Matrix Metalloproteases (MMP) that degrade 
collagens and laminin in the basal lamina 
[36]
. The loss of vascular integrity 
leads to breakdown of the blood-brain-barrier and development of cerebral 
edema. Catastrophic loss of vascular integrity is postulated to cause 
haemorrhagic conversion of ischemic infarction by allowing extravasation of 
blood constituents into the brain parenchyma
 [37 ]
. 
CEREBRAL EDEMA 
  Cerebral edema complicating stroke can cause secondary damage by 
several mechanisms, including increased intracranial pressure, which may 
decrease cerebral blood flow, and mass effect causing displacement of brain 
tissue from one compartment to another (ie, herniation), a process that can be 
life-threatening. 
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Two types of cerebral edema can occur as a consequence of ischemic 
stroke . 
1. Cytotoxic edema is caused by the failure of ATP-dependent 
transport of sodium and calcium ions across the cell membrane. 
The result is accumulation of water and swelling of the cellular 
elements of the brain, including neurons, glia, and endothelial 
cells. 
2. Vasogenic edema is caused by increased permeability or 
breakdown of the brain vascular endothelial cells that constitute 
the blood-brain barrier 
[ 38-39]
. This allows proteins and other 
macromolecules to enter the extracellular space, resulting in 
increased extracellular fluid volume. 
    About 10% of ischemic stroke may be massive because of the 
presence of space-occupying cerebral edema that may be severe enough to 
produce elevated intracranial pressure and brain herniation.  
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RISK FACTORS ASSOCIATED WITH STROKE 
  Atherosclerosis is the common basic cause in both cerebrovascular 
and cardiovascular related morbidity and mortality. The major risk factors 
associated with stroke and myocardial infarction include 
[40-44] 
. 
 Systemic Hypertension 
 Diabetes mellitus 
 Smoking 
 Dyslipidemia 
    As we all know the risk increases more with combination of two or 
more risk factor. This was proved by a study conducted in 3998 subjects and 
assessed the severity of carotid stenosis and found that the carotid stenosis 
increased as the number of risk factors increased. This study also founded 
that this incidence was more among men than women.
[45]
: 
 Without any risk factors the incidence of a severe stenosis was 2.4 and 
0.6 % in men and women respectively. 
 With single risk factor it was 6.7 and 1.5 %. 
 With two risk factors it was 10.7 and 2.7 % 
 With three risk factors it was 18.6 and 5 %. 
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Therefore control of these risk factors will provide an additional 
benefit as this risk factor control also reduces the risk of cardiovascular 
events, a common comorbidity in patients with cerebrovascular disease.  
HYPERTENSION  
     Hypertension, which has a crucial role in the formation of 
atherosclerotic lesions, is an important as well as treatable risk factor for 
cerebrovascular accident. 
 Hypertension is present in approximately 60 % of men and women in 
all age groups. 
 Hypertension can cause either a silent or subclinical stroke and it is 
also one of the important risk factor for recurrent stroke and dementia 
due to vascular pathology. [46-48] 
 Mean blood pressure is an important risk factor for stroke. In addition 
to that  there is evidence to say that visit to visit variability in systolic 
blood pressure is also a risk factor for stroke.
[49,50]  
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FIGURE-5 
 
     ASA/AHA Guidelines 2011 includes antihypertensive regimen andlife 
style modifications viz. 
[51] 
1.Salt restriction   
2.Weight loss 
3.Vegetables 
4.Diet rich in fruits 
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5.Regular aerobic physical activity 
6.Low-fat dairy products  
7.Limited alcohol consumption. 
     Scottish heart health study was a random population survey conducted 
among Scottish people.10359 men and women participated, out of which 
plasma fibrinogen was measured in 8824 patients. 
The result from that study confirms that plasma fibrinogen is not only 
a risk factor for stroke and coronary heart disease, this plasma fibrinogen 
value was also increased in patients with family history of premature heart 
disease , Smokers , Diabetes, Hypertension and intermittent claudication.   
SMOKING  
   Smoking is an important risk factor for all stroke subtypes. In various 
studies it was found that there exists a dose response relationship for both 
subarachnoid haemorrhage and ischaemic stroke.
[52-57] 
Both males and females are affected equally among smokers but as the 
age progresses the association seems to become weaker. There is perhaps an 
association with passive smoking also.  
Up to one half of all smokers are expected to die from a tobacco-
related mortality 
[ 1 ]
. In one population-based cohort study which involves 
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about 50,000 people aged between 40 to 70 years in Norway, the total years 
of life lost were 2.7 years in men and 1.4 years in women, among those who 
smoked ≥20 cigarettes daily, compared to those who never smoked. 
In the Nurses' Health Study, it was found to have that smokers had a 
relative risk of stroke of 2.58 compared with patients those who never 
smoked
[53] 
. 
 Another interesting fact found in this study was that the excess risk 
disappeared within two to four years among the former smokers after 
cessation of smoking. 
 In the Framingham Heart Study, it was found that the odds ratio was 
1.08 for moderate carotid stenosis, for each five pack-years of 
smoking 
[55] 
. 
 10,938 normotensive subjects were studied in a prospective Swedish 
cohort study, and found to have about 39% of strokes were attributable 
to smoking 
[56]
. 
     Though there is no randomized controlled trials relating both smoking 
cessation and stroke prevention, few observational studies have shown that 
the increased risk of stroke due to smoking declines after quitting and is 
eliminated by five-years of smoking cessation
[57-58]
. Hence smoking 
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cessation is recommended, for patients with transient ischemic attack (TIA) 
and stroke. 
  In addition to cigarettes, tobacco is also smoked in the form of pipes, 
cigars, and water pipes. Tobacco products get absorbed through mucosal 
membranes after tobacco chewing and snuffing. Electronic cigarettes (e-
cigarettes) use a liquid nicotine cartridge, rather than tobacco.  
In two Nottinghamshire studies which compares smokers with non-
smokers, chronic smokers had a significantly elevated absolute rate of 
fibrinogen synthesis. Moreover, abstinence from smoking for a period of 
only 2 weeks results in significant decrease in fibrinogen synthesis by the 
liver, thereby concomitantly reduces the plasma fibrinogen concentration.  
DIABETES MELLITUS  
      When compared to those who are non-diabetic the risk of stroke is 
double in patients with diabetes[59-62]. Endothelial dysfunction, Dyslipidemia, 
platelet and other coagulation abnormalities promotes the development of 
carotid atherosclerosis in diabetics.  
       Studies also proved that impaired glucose tolerance and increased 
HbA1c are associated with carotid plaque development 
[64,65]
.  
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GLYCEMIC CONTROL   
        Strict glycemic control reduces the risk of microvascular 
complications such as nephropathy, retinopathy and neuropathy in patients 
with diabetes mellitus. 
       However, randomized controlled trials failed to demonstrate a 
consistent beneficial effect of lifestyle modification or intensive glucose 
lowering therapy on macrovascular outcomes such as cardiovascular events 
and death in patients with Type 2 Diabetes.  
In contrast, the results of the UKPDS post-trial observation follow-up 
study suggest that initial intensive control of Hb A1C to7.0 % in individuals 
who was newly diagnosed diabetes has long-term benefit in decreasing the 
risk of stroke, myocardial infarction, diabetes related mortality, and overall 
mortality.  
    In one study by Ang et al there was a significant interaction between 
fibrinogen and diabetes mellitus and they also established lower platelet 
inhibition when treated with clopidogrel if diabetes and elevated plasma 
fibrinogen coexist. 
[63] 
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  METABOLIC SYNDROME  
    The metabolic syndrome was defined as three or more of the 
following factors.  
1. Hypertension , 
2. High fasting glucose,  
3. Abdominal obesity , 
4. Low high-density lipoprotein, 
       The available evidence will not satisfactorily explain that metabolic 
syndrome is an independent risk factor for stroke 
 A prospective cohort study which includes 14,284 patients with 
coronary heart disease found that the risk for TIA or stroke was 
independently associated with the presence of metabolic syndrome as 
with frank diabetes as well as patients without diabetes, corresponds to 
odds ratios 2.3 and 1.5, respectively
[64]
.  
  Another population-based prospective cohort study followed 3298 
stroke-free subjects in which 44 % of whom had metabolic syndrome 
for a mean of 6.4 years 
[65]
. After adjusting for age, sex, ethnicity, 
socioeconomic status, and other risk factors, the metabolic syndrome 
was associated with a high risk of ischemic stroke. 
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  In the prospective ARIC study which includes 14,993 middle-aged 
subjects who were stroke-free at baseline, metabolic syndrome was 
present in 39%
[66]
. There was a dose-response relationship between the 
number of metabolic syndrome components and risk of ischemic 
stroke. Elevated fasting glucose and Elevated blood pressure were the 
two components that conveyed the highest risk. 
    The utility of the metabolic syndrome to predict stroke risk does not 
appear to improve upon more conventional assessments such as the 
Framingham Risk Score (FRS). In a prospective study of 5128 middle-aged 
men with no history of stroke or coronary heart disease, presence of the 
metabolic syndrome was associated with a significant increase in stroke risk, 
but the FRS was significantly more effective for predicting stroke rather than 
the number of metabolic abnormalities 
[67]
. 
DYSLIPIDEMIA  
  Hyperlipidemia is an important risk factor for myocardial infarction. 
But the relation between blood lipids and stroke is not well established.  
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OTHER FACTORS INFLUENCING RISK 
ALCOHOL INTAKE  
     Depending upon the type of stroke, level of consumption, and 
ethnicity, alcohol affects the risk of stroke in contradictory directions. 
Patients having binge drinking or consuming large amount periodically is 
associated with an increased risk of stroke as compared to patients who take 
alcohol occasionally or in smaller amounts. AHA/ASA guidelines 2011 
recommends that patients with previous history of stroke should eliminate or 
reduce their alcohol consumption to avoid the alcohol based morbidity and 
mortality.   
   In one study which was conducted in French population as a part of  
DESIR study, fibrinogen value was found to be higher in subjects who are 
non-alcoholic or who consume more than 60g of alcohol per day. And 
another fact found in this study was increased value in subjects consuming 
beer and spirits than those who consume wine or cider. And moderate 
amount of drinking lowers the fibrinogen value. Hence this can be attributed 
to protective effect of alcohol on cardiovascular disease. 
APOLIPOPROTEIN- E  
     The role of apolipoprotein E (APOE) phenotypes in cerebrovascular 
disease and ischemic stroke is unsettled. This apolipoprotein helps in 
clearance of VLDL and chylomicron remnants from the circulation. The 
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APOE e4 allele has been reported to be a stroke risk factor in some 
studies
[68]
.  
HYPERHOMOCYSTEINEMIA    
    Increased serum homocysteine concentrations are associated with an 
increased risk of coronary and cerebrovascular disease. 
Homocysteine has prothrombotic and primary atherogenic properties. 
The pathologic features of vessel wall include intimal thickening, disruption 
of elastic lamina, smooth muscle proliferation, platelet aggregation, and the 
formation of platelet rich thrombi. 
     Elevated homocysteine seems to be associated with an increased risk 
of the atherosclerosis in large artery, and possibly in small artery and  it does 
not appear to be associated with cardioembolic or other stroke subtypes 
[69]
.   
       Unfortunately, there is no evidence that treating 
hyperhomocysteinemia with folic acid and vitamins will prevent the 
recurrent events.  
          For patients with hyperhomocysteinemia, the AHA/ASA guidelines of 
2011 states that folic acid can be given to reduce the homocysteine levels. 
However, there is no clear cut data or evidence to prove that reducing 
homocysteine level prevents stroke recurrence.  
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INFLAMMATORY MARKERS  
Mounting data suggest that inflammation plays a role in 
atherosclerosis and contributes to stroke risk. 
C-REACTIVE PROTEIN  
    C-reactive protein (CRP) concentration is associated with the long-
term risk of atherosclerotic vascular events, including ischemic stroke and 
myocardial infarction, as confirmed by a meta-analysis of 54 prospective 
studies and individual records from over 160,000 subjects without a history 
of vascular disease
[70]
. 
    While elevated CRP levels could be used as an additional marker of 
increased stroke risk, there are no randomized clinical trial data to support 
the hypothesis that lowering CRP levels will lead to reduced stroke risk. 
Furthermore, appropriate critical thresholds of CRP elevation and optimal 
timing of CRP measurements in the setting of acute cerebral ischemia have 
not been established. Hence routine checking of CRP levels are not 
recommended for primary or secondary ischemic stroke prevention.
 
FIBRINOGEN   
      Plasma fibrinogen is associated with the increased risk of stroke and 
cardiovascular disease. This fibrinogen acts by several possible mechanisms, 
including promotion of atherogenesis and inflammation, elevation of blood 
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and plasma viscosity, increased platelet aggregation, and increased tendency 
to form fibrin within thrombus. 
    Elevated fibrinogen levels appear to correlate with vulnerable 
atherosclerotic plaque characteristics, including thinning of the fibrous cap 
of atheroma predisposing to rupture, and to increased plaque inflammation 
[71]
. However, it is not established that elevated fibrinogen is an independent 
risk factor for carotid atherosclerosis progression, as some evidence suggests 
it is rather a nonspecific marker of inflammatory activity. 
     Due to the lack of clinical trial data, measuring plasma fibrinogen is 
not recommended routinely in all stroke patients. Still more studies are 
needed to study about the drug therapy specifically aimed at lowering the 
fibrinogen concentrations for patients at risk of ischemic stroke or 
progressive carotid disease. 
LEUKOCYTES  
          Leukocyte counts and neutrophil counts were associated with ischemic 
events including stroke, myocardial infarction, and vascular death in a high-
risk population. In the week before the recurrent event, the leukocyte count 
was significantly increased over the baseline value. However, treatment 
with aspirin or clopidogrel did not modify the predictive effects of elevated 
leukocyte counts. 
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          An independent association of leukocyte count elevation with 
increased ischemic stroke risk was also found among stroke-free participants 
in a prospective, longitudinal, cohort study (the Northern Manhattan Study). 
RADIOTHERAPY  
          Head and neck radiotherapy for cancer treatment may lead to a 
delayed vasculopathy of large and small vessels mediated by endothelial 
damage, fibrosis, and accelerated atherosclerosis. Radiotherapy-related 
occlusive disease is often diffuse and occurs in uncommon locations, in 
contrast to the typical focal lesions that develop at vessel bifurcations from 
atherosclerosis in the absence of radiation. 
     Depending on the site and dose of radiation, the involved vessels may 
include the extracranial carotid and vertebral arteries and the intracranial 
circle of Willis vessels. This process may lead to symptomatic carotid 
disease, moyamoya syndrome, and ischemic stroke.  
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ANATOMY OF CEREBRAL CIRCULATION 
    At rest, the brain which is only 2% of total body weight, receives 20% 
of the cardiac output and consumes 20% of the total inspired oxygen. This 
rich blood supply is delivered by the two internal carotid and two vertebral 
arteries, which anastomose at the base of the brain to form the circle of 
Willis. The carotid arteries supply the anterior, and the vertebra basilar 
arterial system supplies the posterior portions of the brain. 
    There is individual variation in the branches of the main cerebral 
arteries and also there is considerable variation between the individuals in 
the usual brain territories of supply of the various major arteries, and these 
territories can be asymmetrical and even change with time, depending in part 
on the availability of functional collaterals. 
    The Internal Carotid artery (ICA) starts from bifurcation of the 
common carotid artery (CCA) at the level of upper border of thyroid 
cartilage. The artery gives no branches in the neck to the skull base. The 
artery then passes into foramen lacerum. This artery enters into carotid canal 
which is present in the petrous part of temporal bone. It then traverses 
cavernous sinus and enter the duramater. This artery exits just medial to the 
anterior clinoid process, and then divides into the anterior cerebral artery and 
the larger middle cerebral artery. 
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     The external carotid artery also starts at the CCA bifurcation and 
supplies the jaw, face, scalp, neck and meninges .The ophthalmic artery 
supplies the eye and orbit. 
     The Posterior communicating artery arises from internal carotid artery. 
This artery runs backwards and joins with posterior cerebral artery thereby 
closing the circle of Willis. The branches from this artery supply the 
thalamus, midbrain and radiations for visual pathway. 
 
 
                             FIGURE-6 BLOOD SUPPLY OF BRAIN 
 
44 
 
The anterior choroidal artery is the final branch from internal carotid 
artery that supplies the capsulo-ganglionic region, optic radiations and 
temporal lobes. 
Anterior cerebral artery (ACA) passes horizontally and medially to 
enter the interhemispheric fissure, anastomoses with its counterpart of the 
opposite side via the anterior communicating artery (ACoA), curves up 
around the genu of the corpus callosum, and supplies the anterior and medial 
parts of the cerebral hemisphere. Small branches also supply parts of the 
optic nerve and chiasma, hypothalamus, anterior basal ganglia, and internal 
capsule.  
The ACA is divided into two segments- 
1.The pre communal (A1) segment, or the stem which connects the internal 
carotid artery to the anterior communicating artery and 
2.The post communal (A2) segment distal to the anterior communicating 
artery. 
     The middle cerebral artery (MCA) enters the sylvian fissure and 
divides into 2-4 branches which supply the lateral parts of the cerebral 
hemisphere. 
The proximal MCA (M1 segment) gives rise to penetrating branches 
(lenticulostriate arteries) that supply the putamen, outer globus pallidus, 
posterior limb of internal capsule, the adjacent corona radiata and most of 
the caudate nucleus. In the Sylvian fissure, the MCA in most patients divides 
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into superior and inferior divisions (M2 branches). Branches from the 
inferior division supply the inferior parietal and temporal cortex, and those 
from the superior division supply the frontal and superior parietal cortex.  
     The vertebral artery arises from the proximal subclavian artery and 
ascends to pass through the transverse foramina of the sixth to second 
vertebrae. It unites with the opposite vertebral artery on the ventral surface of 
the brain stem at the pontomedullary junction to form the basilar artery. The 
vertebral artery gives rise to the anterior and posterior spinal arteries, the 
posterior inferior cerebellar artery and small penetrating arteries to the 
medulla. The posterior inferior cerebellar artery supplies the inferior vermis, 
inferior and posterior surfaces of the cerebellar hemispheres and brain stem.  
     The basilar artery ascends ventral to the pons to the pontomidbrain 
junction in inter peduncular cistern where it divides into the two posterior 
cerebral arteries (PCA).Numerous small branches penetrate the brainstem 
and cerebellum. The basilar artery also gives rise to the anterior inferior 
cerebellar artery which supplies the rostral cerebellum, brainstem, inner ear, 
and the superior cerebellar artery which supplies the brainstem, superior half 
of cerebellar hemisphere, vermis and dentate nucleus. 
    The posterior cerebral artery (PCA) encircles the midbrain close to the 
oculomotor nerve at the level of the tentorium and supplies the inferior parts 
of the temporal lobe and the occipital lobe. Many small perforating arteries 
arise from the P1 segment of posterior cerebral artery to supply the midbrain. 
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There is an anatomic variant in which both the medial surface of thalamus 
receive a common blood supply from single arterial trunk called ARTERY 
OF PERCHERON. The posterior cerebral artery also supplies thalamus, 
hypothalamus and geniculate bodies. In about 15% of individuals the PCA is 
a direct continuation of the PoCA, its main blood supply then coming from 
ICA rather than the basilar artery. 
COLLATERAL BLOOD SUPPLY TO THE BRAIN 
     Normally the ICA provides blood to the anterior two-thirds of the 
ipsilateral cerebral hemisphere. There is rather little mixing of blood via the 
PoCA and so the posterior circulation is usually supplied by the vertebral, 
basilar and posterior cerebral arteries. However there are several ways in 
which collateral blood supply to the brain can develop distal to the occlusion 
of major arteries in the neck or head. The actual pattern of collateral blood 
flow depends on where the major vessels are stenosed or occluded, and on 
which collateral channels are anatomically available in a particular 
individual, and free from disease. Collateral blood flow may develop from 
the circle of Willis, which is formed by the proximal part of the two ACA’s 
connected by the ACoA, and the proximal part of the two PCA’s, which are 
connected to the distal ICA’s by the PoCA.  
Other areas of collateral blood flow are: 
1. Around the orbit 
2. Leptomeningeal anastomoses 
3. Parenchymal anastomoses  
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FIGURE-7 CEREBRAL CIRCULATION 
 
 
VENOUS DRAINAGE 
    Venous blood flows centrally via the deep cerebral veins and 
peripherally via the superficial cerebral veins into the dural venous sinuses 
which drain into the internal jugular veins. The cerebral veins are thin 
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walled, have no valves and the blood flow is often in the same direction as in 
neighbouring arteries
 [72]
. 
FIBRINOGEN 
STRUCTURE 
[73-74]
 
The fibrinogen is synthesized by liver and secreted in plasma. The 
fibrinogen molecule is a large trinodular di sulphide bonded glycoprotein 
composed of two symmetric half molecules. Each half molecule contains 
three distinct polypeptide chains called Aα, Bβ and γ chains. The entire 
molecule has a molecular mass of 3,40,000 Dalton and is 45nm long and 
9nm in diameter. The central nodule or E-domain is 5nm in diameter and 
contains the NH-2 terminal of all six polypeptide chains forming the NH-2 
terminal disulphide knot. The outer two D-domain nodules are composed of 
the C-terminal two thirds of both the Bβ and γ chains. X-ray diffraction 
studies suggest that the Bβ and γ chain each form an independent subdomain 
within the D-domain. These two subdomains are located diagonally along 
the long axis of the molecule. Between the E- and D- domains, there is a 
stretch of approximately 120 amino acids from each of the three chains that 
forms an α- helical structure known as the “coiled coil domain”. This region 
of the molecule is supported on both the sides by a set of disulphide bonds 
called disulphide rings. These rings play an important role in making fibrin 
mechanically strong and resistant to proteolysis. 
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The Aα chain is a 610 amino acid polypeptide. It is divided into three 
distinct domains. The first section of Aα chain (residues 1-194) contains a 
region (residues 45-161) linked to the Bβ and γ chains by disulfide bonds. 
This section  
FIGURE - 8 
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forms part of the α-4helix or coiled coil domain. This first section also 
contains fibrinopeptide-A (residues 1-16) and the polymerization site in the 
E-domain. 
The middle third of the molecule (residues 240-424) is extremely rich 
in a polar amino acids and contain 10 tandem repeats each 13 amino acids 
long. The region bridging these first two sections (residues 195-239) is 
composed of a protease sensitive domain containing a high content of 
pralines as well as several plasmin cleavage sites. There are two glutamine 
residues in the midsection that serve as important cross-linking receptor sites 
for factor XIIIa. Within the hydrophilic C-terminal third molecule (residues 
425-610) are the  cross-linking sites for both fibronectin and α-2 antiplasmin. 
There are also two RGD (arginine, glycine and aspartic acid) sequences 
(residues 95-97 and 572-574) located in the Aα chain which play a role in 
cellular adhesion events. 
The Bβ chain is a polypeptide composed of 461 amino acids and is 
also divided into three sections. The first 80 residues contain the 
fibrinopeptide B sequence (residues 1-15) and a site that supports endothelial 
cell spreading and proliferation (residues 15-42) The middle section 
(residues 81-192) is linked to the Aα and γ chains through disulphide rings 
and forms part of the coiled-coil domain. The C-terminus of the Bβ chain 
forms one of the independently folded sub domains of the D-domain. 
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    The γ chain is only 411 amino acids long and is also divided into three 
distinct sections. Unlike the Aα and Bβ chains, there is no fibrinopeptide at 
the NH2- terminus of the γ chain. The first 18 amino acids of the γ chain 
form part of the NH2-terminal disulfide knot. The middle segment of this 
polypeptide consists of amino acids 19-135. This section contains the 
disulfide rings that link this region to the Aα and Bβ chains in the coiled-coil 
domain. The C-terminal section containing amino acids 136-411 forms a 
globular sub domain of the D-domain. Within this region is the D-domain 
polymerization site, the factor XIIIa cross-linking sites, and the binding 
domain important for platelet aggregation (residues 400-411) 
     There are 2 distinct forms of the γ chains in the human plasma 
fibrinogen. Approximately 15% of the γ chain contain an extended C-
terminal and are designated γ1 chains. The γ1 chain is produced by 
alternative polyadenylation of the last intron of the γ chain gene. Although 
fibrin polymerization and cross linking of γ1 proceed normally, the γ1 chain 
does not support platelet aggregation. The clinical significance of the γ1 
chain remains unknown; however, recent studies suggest that γ1 is a carrier 
for zymogen of factor XIII in circulating blood. 
      The Bβ and γ chains of fibrinogen contain asparagine residues that 
serve as N-glycosidic linkages for carbohydrate attachment. In a variety of 
diseases involving hepatic injury, a fetal form of fibrinogen is produced that 
has increased amounts of sialic acid attached to the carbohydrate side chains. 
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This results in defective fibrin polymerization, and is associated with 
hepatomas and cirrhosis. The polymerization defect in fetal fibrinogen does 
not cause any bleeding disorder, although it can produce a significant 
prolongation of clotting time when assayed in vitro. 
     Electron microscopic examination has revealed a trinodular structure 
with a central nodule (fragments E) linked through 2 thin rods (fragments D) 
to two peripheral nodules. 
SYNTHESIS 
       Plasma fibrinogen is synthesized exclusively by the hepatocyte, and 
the synthesis of the three chains is under the coordinated control of three 
separate genes localized on chromosome 4(ch4q23-q32). Subsequent to the 
assembly of the constituent polypeptide chains and the addition of 
carbohydrate side chain (3%), the mature molecule is secreted into the 
circulation, where it manifests the half-life of 72-108 hours and fractional 
catabolic rate of 25% per day. The turnover rate of fibrinogen is about 1.7-5 
gm/day (30-60mg/kg/day). 
FUNCTION 
Fibrinogen plays the central role in three major functional processes. 
1. The soluble fibrinogen molecule is converted into insoluble fibrin during 
the process of blood coagulation. 
2. The polymerized fibrin serves as a template for the localized assembly and 
activation of the fibrinolytic system, which modulates fibrin deposition and 
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clot dissolution.  
3. Fibrinogen binds to vascular cells such as platelets, where it supports 
platelet aggregation by binding to platelet GP IIb-IIIa receptors and to 
endothelial cells, where it participates in tissue repair 
The conversion of fibrinogen into insoluble fibrin can be divided into 
three distinct phases. 
1. Enzymatic cleavage of fibrinopeptide by thrombin. 
2. Fibrin polymerization.  
3. Fibrin stabilization, via covalent cross-linking by factor XIIIa. 
FIBRINOGEN ABNORMALITIES 
Classified as congenital or acquired, with both groups manifesting 
quantitative defects or qualitative differences of fibrinogen molecules. In few 
instances, both quantitative and qualitative abnormalities can be present in 
the same patient. 
a) CONGENITAL DISORDERS 
i. Congenital Afibrinogenemia and Hypofibrinogenemia 
They are familial and cause bleeding disorders of varying severity 
from birth. Sometimes low fibrinogen may be an abnormal molecule then it 
is called hypodysfibrinogenemia. CT, PT and aPTT are abnormal. 
ii. Congenital dysfibrinogenemia. 
It is characterized by biosynthesis of a structurally abnormal fibrinogen 
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molecule that exhibits altered functional properties and commonly exhibits 
an abnormal thrombin mediated conversion to fibrin. The various mutants 
described carry the name of the city of origin of the patient initially affected 
with a particular dysfibrinogenemia. Functional abnormalities are usually 
reflected as abnormalities in one or more phases of fibrinogen to fibrin 
conversion.  
These include: 
1. Impaired release of fibrinopeptides. 
2. Defects in fibrin polymerization. 
3. Failure of polymerized fibrin to undergo normal covalent 
stabilization by factor XIIIa. 
4. Abnormal interaction with platelets, endothelial cells or calcium. 
    Most patients are asymptomatic. Prothrombin time is prolonged. 
Plasma fibrinogen concentration is normal when measured immunologically 
and the discrepancy between clotable protein and immunologically measured 
fibrinogen is a characteristic feature of dysfibrinogenemia. 
b.) ACQUIRED DISORDERS 
HYPERFIBRINOGENEMIA 
Various causes for elevated fibrinogen level are, 
1. Advanced age: It has been observed in various epidemiological studies 
that plasma fibrinogen level increases with increasing age. 
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2. Gender: Males have a higher fibrinogen levels than females. 
3. Race: Fibrinogen is about 0.2gm/L higher in blacks than in whites. 
4. Smoking: Smoking is a very important influencing factor for fibrinogen 
levels. There is a positive correlation between smoking and plasma 
fibrinogen levels; fibrinogen level begins to fall soon after smoking is 
discontinued. The consistent observation of higher plasma fibrinogen levels 
in heavy smokers, independent of age, may be explained by two hypothesis; 
a) Smoking may lead to endothelial damage resulting in activation of the 
coagulation system. 
b) Smoking activates lung macrophages which release interleukin-6 
increasing liver synthesis of fibrinogen
[75]
. 
5. Physical inactivity: There is an inverse relationship between physical 
activity and fibrinogen concentration. 
6. Diet: Diet rich in carbohydrates and fat and diet poor in ω-3 and ω-6 
PUFA’s and fibre are associated with raised fibrinogen levels. 
7. Excess body weight: In obese patients, plasma viscosity and fibrinogen 
levels are increased. 
8. Hyperlipidemia: 
9. Diabetes Mellitus. 
10. Hypertension 
11. Ischemic heart disease:  
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12. Left ventricular dysfunction: There is an increased risk of intracardiac 
thrombus and systemic thromboembolism in patients with poor cardiac 
function, especially in those with ventricular aneurysm and dilated 
cardiomyopathy. The increased risk of thrombosis in patients with left 
ventricular dysfunction is increased because of increased fibrinogen levels as 
compared to patients with normal left ventricular function
[76]
. 
13. Atrial fibrillation- Plasma fibrinogen levels are elevated in patients with 
chronicatrial fibrillation. 
14. Psychological and mental stress- It has been shown to increase plasma 
fibrinogen concentration. 
15. Cerebrovascular disease- Increased fibrinogen was correlated with 
stroke and TIA incidence and progression of carotid atherosclerotic lesion
[77]
. 
Peripheral vascular disease is associated with increased fibrinogen 
concentration. Fibrinogen levels have been found to be higher in those 
women who are taking oral contraceptives and in postmenopausal age.  
16.Social class- Fibrinogen has been found to be higher in lower 
socioeconomic class. 
17. Family history of IHD -Fibrinogen is raised in individuals with family 
history of ischemic heart disease. 
18. Genetic factors- There is a significant genetic influence on plasma 
fibrinogen formation and genetic inheritability may account for up to 51% of 
variance of the plasma fibrinogen level. Variation at the beta fibrinogen 
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locus has been thought to affect fibrinogen concentration, because the beta 
gene control formation of Bβ chains, the rate limiting step in fibrinogen 
synthesis. Individuals with B1B2 genotype who have high fibrinogen levels 
are at increased risk of atherosclerosis
[76]
. 
19. Dental disease- Chronic inflammatory gingival and periodontal infection 
causes elevation in the levels of plasma fibrinogen. 
20. Elevated leukocyte count- It is associated with increase in fibrinogen 
concentration. 
21. Acute inflammation and infections- Fibrinogen increases by three fold 
in response to acute inflammation as an acute phase response. 
HYPOFIBRINOGENEMIA 
Hypofibrinogenemia occurs in, 
i. Decreased hepatocyte biosynthesis due to fulminant hepatic failure, 
decompensated liver cirrhosis. 
ii. Disseminated intravascular coagulation due to increased consumption. 
iii. Use of drugs like L-asparaginase, valproic aced. 
iv. Alcohol consumption has a small but significant effect on decreasing 
plasma fibrinogen. A decrease of approximately 0.78% per 10gm of alcohol 
consumed has been noted. 
v. Fibrinolytic therapy reduced fibrinogen levels for a day or two. 
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DYSFIBRINOGENEMIA: 
Dysfibrinogenemia of liver disease 
About 50% of patients with cirrhosis or hepatitis or hepatoma exhibit 
dysfibrinogenemia characterized functionally by impaired polymerization of 
fibrin. Similar changes have also been observed in hypernephroma as a part 
of paraneoplastic syndrome. 
     Antibodies against fibrinogen can cause functional abnormalities of 
fibrinogen as seen in SLE, ulcerative colitis and post-necrotic cirrhosis or 
sometimes can be idiopathic. Inhibition of fibrin monomer polymerization is 
seen in multiple myeloma. 
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MATERIALS AND METHODS 
This study was conducted in our medical college hospital. Patients 
were recruited from medicals wards and IMCU. A total of about 110 patients 
were selected and 10 of them were excluded as per exclusion criteria used. 
The remaining 100 patients were included in the study.  Informed consent 
was obtained from all patients. Plasma fibrinogen value was estimated in all 
100 patients admitted with stroke who got admitted within 24 hours of stroke 
onset. 
INCLUSION CRITERIA 
Patients who got admitted in our hospital within 24 hours of the onset 
of stroke. 
EXCLUSION CRITERIA  
1. Patients admitted with stroke more than 24 hours from onset.   
2. Patients refused to give consent for the study, 
3. Patients having renal failure, 
4. Inflammatory disease, 
5. Active viral hepatitis,  
6. Infection,  
7. Severe dehydration  
8. History of myocardial infarction or 
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9. Surgery in 3 months. 
10. Patients  having space occupying lesions, 
11. Subdural hematoma. 
METHODOLOGY 
   For all the 100 cases admitted, detailed clinical examination done and 
history was taken regarding smoking, alcohol, diabetes, hypertension, 
coronary heart disease, renal disease, any infection, surgery, trauma. Blood 
sugar, ECG and routine investigation was done. CT BRAIN was done in all 
patients to classify ischemic or haemorrhagic stroke. And for all the patients 
in our study Scandinavian stoke scale was calculated at the time of 
admission. Also modified Rankin score was calculated in all the patients 
during the time of admission and discharge.    
Plasma fibrinogen was measured in all these 100 patients who are 
included in the study and the values interpreted.   
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PLASMA FIBRINOGEN 
MEASUREMENT OF FIBRINOGEN 
[78-79] 
There are many fibrinogen assays available in various laboratories. 
Out of all, the clauss method is the one that is most commonly used to 
determine plasma fibrinogen value in most of the laboratories. Few of the 
tests are designed for an emergency situation where we need only to know 
whether the value is elevated or decreased. The exact fibrinogen value is not 
needed at certain times. 
PREREQUISITE 
      WHO recommends tri-sodium citrate to be used as an anticoagulant 
for determining plasma fibrinogen value. The strength most commonly used 
is 0.105 to 0.109m.  
The sample to be used should contain 1 part of anticoagulant and 9 
parts of blood. Under strict aseptic precautions the blood should be drawn 
rapidly from the venepuncture site with minimal stasis and transferred to 
citrated container. 
This sample should be inverted gently to look for any clots. In the 
presence of clot or hemolysis the sample should not be used and discarded as 
this may interfere with fibrinogen value. The blood sample collected can be 
stored at room temperature. 
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PREPARATION OF PLASMA  
The sample collected should be subjected to centrifuge to remove the 
platelets. This centrifugation can be performed in room temperature. The 
resultant plasma can be used immediately or stored in deep freeze at -70
0
C 
for maximum of 18 months. The photo optical methods used in 
determination of fibrinogen may interfere with the samples that are lipaemic 
or icteric and hence these samples should be avoided.  
In case of frozen plasma the sample should be thawed for 5 minutes at 
37
0
C and mixed by inversion before doing analysis.
 
FIBRINOGEN ASSAYS 
[80] 
1. CLAUSS ASSAYS 
        It is the most commonly performed method to determine plasma 
fibrinogen value. This test based on the rate of clot formation in dilute 
citrated plasma following the addition of thrombin. The clotting of dilute 
plasma is inversely proportional to the plasma fibrinogen concentration 
when high concentration of thrombin is used. In this procedure a high 
concentration of thrombin say 100μ/ml is added to platelet poor plasma and 
the clotting time is measured.  
        The high concentration of thrombin that is added to plasma ensures 
that wide fibrinogen values are independent of thrombin concentration. . The 
clotting end point is measured by either mechanical or photo-optical means, 
as these methods have shown excellent cross correlation and precision.  
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The results are plotted in a calibration curve made from clotting times 
with serial dilution and fibrinogen concentration. The result obtained will be 
in mg/dl. 
    As this type of assay measures the time to formation of a detectable 
clot, the presence of inhibitors of fibrin polymerization, such as fibrinogen 
and14 fibrinogen degradation products results in under estimation of the 
actual fibrinogen concentration. 
The normal reference value is 200 to 400 mg/dl. 
PT - BASED TESTS  
In this method prothrombin time is determined by optical density 
change in platelet poor plasma and compared with derived fibrinogen in a 
calibration curve. 
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FIGURE-9 COAGULATION CASCADE 
 
 
 
 
The other methods to determine fibrinogen include; 
1. Gravimetric method 
2. Immunological 
3. Salting out. 
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SCANDINAVIAN STROKE SCALE (SSS) 
CONCIOUSNESS 
 Fully conscious  - 6 
 Somnolent, awaked to full conscious level-4 
 Not fully conscious, but reacts to verbal commands-2 
 Coma-0 
Eye movement 
 Without gaze palsy-4 
 With gaze palsy-2 
 Conjugate eye deviation-0 
Speech 
 Without aphasia-10 
 Limited expression or comprehension-6 
 More than yes or no, but no longer sentences-3 
 Only yes or no or less than that-0 
Orientation 
 Oriented to person place and time-6 
 Any two present-4 
 Any one present-2 
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 Fully disoriented-0 
Gait 
 Walks 5 or more meter without aid-12 
 Can walk with aid-9 
 Can walk with another person help-6 
 Sits without any support-3 
 Wheelchair bound or bedridden-0 
Facial palsy 
 Absent-2 
 Present-0 
Arm, motor power (tested on affected side) 
 Can lift the arm with normal power-6 
 Can lift the arm with reduced power-5 
 Raises the arm with flexion in elbow-4 
 Able to move but not against gravity-2 
 Total paralysis-0 
Hand, motor power (tested on affected side) 
 Normal strength-6 
 Reduced strength in full range-4 
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 Some movement, without fingertip reaching the arm-2 
 Total paralysis-0  
Leg motor power (tested on affected side) 
 Normal strength-6 
 Raises leg with decreased strength-5 
 Raises leg with flexion of knee-4 
 Can move, but not against gravity-2 
 Total Paralysis-0 
MODIFIED RANKIN SCORE (MRS) 
 No symptoms-0 
 No disability despite of the symptoms-1 
 Slight disability present, but does not require any assistance-2 
 Moderate disability, patient can walk without assistance-3 
 Moderately severe disability, not able to walk without assistance-4 
 Severe disability, bedridden and incontinent-5 
 Dead-6. 
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OBSERVATIONS AND RESULTS 
 
AGE DISTRIBUTION 
     Out of 100 patients participated in the study 53 were aged less than 60 
years and 47 were aged more than 60 years. 
The mean age comes around 59. 
 
Age in years Number of patients Percentage 
Less than 60 53 53% 
More than 60 47 47% 
 
 
SEX DISTRIBUTION 
Out of 100 patients 58 were male patients and 42 were female patients. 
Sex Number of patients Percentage 
Male 58 58% 
Female 42 42% 
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SMOKERS 
 Number of patients Percentage 
Smokers 37 37% 
Non smokers 63 63% 
 
Out of 100 persons 37 were known smokers and 63 were non smokers. 
Alcoholics constitute about 19% among the total patients.  
Both the alcoholic and smoking are seen only in men. 
 
ALCOHOLICS 
 Number of patients Percentage 
Alcoholics 19 19% 
Non alcoholics 81 81% 
 
Both smoker and alcoholic were 12% of the patients. 
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SYSTEMIC HYPERTENSION 
40 % of the patients in our study are known case of systemic hypertension. 
 Number of patients Percentage 
Known SHT 40 40% 
Non Hypertensives 60 60% 
 
 
DIABETES 
25% of patients are diabetics in our study. 
Diabetes Number of patients Percentage 
Present 25 25% 
Absent 75 75% 
 
Both diabetes and hypertensive patients were 5% in our study. 
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TYPE OF STROKE 
Ischemic stroke comprises about 88% and haemorrhagic stroke constitutes 
about 12%  
Stroke Number of patients Percentage 
Ischaemic 88 88% 
Haemorrhagic 12 12% 
 
Out of 100 cases 12 cases were expired. In most of the cases the infarct is 
within the middle cerebral artery territory.  
 
AGE 
  In our study the minimum age recorded is 30 years and the maximal 
age is 85 years and the mean age comes 58.87 with standard deviation of 
12.152. 
 N  Minimum Maximum Mean 
Std. 
Deviation 
Age in years 
100 30 85 58.87 12.154 
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SYSTOLIC BLOOD PRESSURE 
The mean systolic blood pressure is 144.4 with lowest recording of 
110 and highest 200 with standard deviation of 21.896.  
 Number Minimum Maximum Mean Standard 
deviation 
SBP 100 110 200 144.40 21.896 
  
DIASTOLIC BLOOD PRESSURE 
     In our study the diastolic blood pressure recorded to the lowest was 
60 and highest was 110 with mean 83.45 and standard deviation 11.38 
 Number Minimum Maximum Mean Standard 
deviation 
DBP 100 60 110 83.45 11.38 
 
SSS 
Scandinavian stroke scale (SSS) is a measure of severity of stroke. 
Total score is 58. Out of which the Scandinavian stroke scale for our patients 
ranges from 4 to 44 with mean value of 29.91 and standard deviation of 
10.107. 
 Number Minimum Maximum Mean Standard 
Deviation 
SSS 100 4 44 29.91 10.107 
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MODIFIED RANKIN SCALE (MRS) 
Modified Rankin scale (MRS) is the one which is used to measure the 
functional outcome of patient in our study. This score ranges from 0 to 6 
which varies from no symptoms to death. This modified Rankin scale is 
calculated at the time of admission and discharge.  
At the time of admission this values varied from 2 to 5 with mean 3.96 
and standard deviation of 0.984. 
During discharge the scale ranges from 1 to 5 with a mean of 2.85 and 
standard deviation of 1.209. This scale is calculated only in 88 patients out 
of 100 as 12 patients were expired during the period of hospital stay. 
 
 Number  Minimum Maximum Mean Standard 
deviation 
MRS-
admission 
100 2 5 3.96 0.984 
MRS-
discharge 
88 1 5 2.85 1.209 
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FIBRINOGEN 
Plasma fibrinogen was measured for all the patients in our study as 
soon as they got admitted. It is noted that lowest value seen in our patients is 
179 and highest value 530. The mean value is 405.46 and standard deviation 
is 83.459. 
 Number Minimum Maximum Mean  Standard 
deviation 
Plasma 
fibrinogen 
100 179 530 405.6 83.459 
 
RANDOM BLOOD SUGAR 
The random blood sugar was estimated in all patients and the results are 
summarised below. 
 Number Minimum Maximum Mean Standard 
deviation 
Random 
blood 
sugar 
100 82 402 207.63 83.459 
 
Then we analysed the correlation coefficient using pearson method. 
We compared fibrinogen value with Scandinavian stroke scale, modified 
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Rankin scale at admission and discharge, systolic blood pressure, diastolic 
blood pressure and random blood sugar. 
The correlation coefficient is more in MRS-admission and discharge 
and Scandinavian stroke scale. 
The correlation between fibrinogen value and Scandinavian stroke 
scale was assessed and found to be statistically significant. 
The P value obtained is <0.01 where the relation is highly significant. 
LEVELS OF CORRELATION WITH PLASMA FIBRINOGEN 
FACTORS CORRELATION COEFFFICIENT 
SBP 0.083 
DBP 0.054 
BLOOD SUGAR 0.231 
SSS 0.506 
MRS-ADMISSION 0.594 
MRS-DISCHARGE 0.582 
 
Similarly modified Rankin scale at the time of admission and 
discharge also correlated with fibrinogen value and found to be statistically 
significant with   P value <0.01.  
76 
 
And also we correlated fibrinogen value with the four important risk 
factors like Diabetes, Smoking, Hypertension and alcoholism. 
Even though the mean value is increased in smokers compared to non-
smokers, in our study we could not establish a statistically significant 
relationship. 
 Mean fibrinogen Standard deviation 
Smokers 412.86 73.364 
Non smokers 401.22 89.197 
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CHARTS AND GRAPHS  
 
 
 
FIGURE-10 AGE DRISTIBUTION 
   This figure depicts that 53 percentage of stroke patients from our study are 
aged less than 60 and 47 percentage above 60. 
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FIGURE-11 SEX DISTRIBUTION 
   This graph depicts the male and female distribution among stroke. 
The prevalence among male is more in this study which comes around 
58%.The important risk factors like smoking and alcohol is exclusively seen 
in males. 
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FIGURE-12 SMOKERS VS NON SMOKERS 
This picture depicts the burden of smoking in stroke. About 37 % of 
total patients in our study group are smokers. This includes present smoking 
and persons who have already quit smoking. 
And the smoking is almost exclusively present only in males. 
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FIGURE-13 ALCOHOLICS VS NON ALCOHOLIC IN STROKE PATIENTS 
In our study the alcoholic constitutes about 19% and remaining 81% 
are non-alcoholics and alcoholism was almost exclusively seen in males. 
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FIGURE-14 TYPE OF STROKE 
In our study the most common type of stroke is ischemic stroke with a 
total of 88% and haemorrhagic stroke constitutes about 12% 
Hence here also it is proved that ischemic is the most common type of 
stroke. 
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FIGURE-15 OUTCOME OF STROKE 
Out of 100 patients 12 patients were expired and 88% discharged.  
Ischaemic stroke is associated with more mortality in our study group. 
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FIGURE-16 AGE DISTRIBUTION 
This diagram depicts the difference in mean fibrinogen value among 
the patients aged less than 60 and more than 60. This picture shows that the 
mean fibrinogen is slightly increased in older individuals with stroke. 
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FIGURE-17 SEX DISTRIBUTION 
    This picture depicts the difference in mean fibrinogen value which is 
slightly higher in female and this increase is not statistically significant. 
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FIGURE-18 STROKE 
     This bar diagram depicts the mean fibrinogen value with ischemic 
stroke. The mean value is higher in ischemic stroke as compared to 
haemorrhagic stroke. 
 
0
50
100
150
200
250
300
350
400
450
Number of Patients Mean
88 
421.5 
12 
287.83 
Stroke 
Ischaemic Stroke
Haemorrahage Stroke
86 
 
 
 
 
FIGURE-19 OUTCOME 
This bar diagram represents that mean fibrinogen value was 
moderately high in patients who expired during the hospital stay. 
The mean fibrinogen in death patients was 439.58. 
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FIGURE-20 FIBRINOGEN WITH SSS 
Scandinavian stroke scale which measured the severity of stroke 
patients admitted in our wards. The mean value was 29.91. The correlation 
between fibrinogen and SSS was statistically significant. 
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FIGURE-21 FIBRINOGEN WITH MRS (ADMISSION) 
This picture compares the mean fibrinogen with Modified Rankin 
scale at the time of admission. The correlation between fibrinogen and MRS 
at the time of admission was statistically significant. 
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FIGURE-22 FIBRINOGEN WITH MRS -DISCHARGE 
This diagram shows the mean value of fibrinogen and mean value of 
modified Rankin scale at the discharge. The mean value of MRS at the time 
of discharge was 2.85 
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FIGURE-23 FIBRINOGEN WITH SBP 
     The mean systolic blood pressure was 144.4 among the stroke patients 
in our study. We could not establish a statistically significant relation 
between fibrinogen and systolic blood pressure. 
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FIGURE-24 FIBRINOGEN WITH DBP 
The mean diastolic blood pressure was 89.75 for our patients in the 
study. 
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FIGURE-25 FIBRINOGEN WITH RANDOM BLOOD SUGAR 
  This diagram represents the mean value of blood sugar was 207.63. 
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COMPARISON OF FIBRINOGEN WITH SMOKERS AND NON 
SMOKERS 
 
 
FIGURE-26 COMPARISON OF FIBRINOGEN WITH SMOKERS 
AND NON SMOKERS 
 
This bar diagram compares the mean fibrinogen value with smokers 
and non-smokers. Although the mean value is increased among smokers we 
could not establish a statistically significant relation between smokers 
fibrinogen. 
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COMPARISON OF FIBRINOGEN WITH ALCOHOLICS 
 
FIGURE-27 COMPARISON OF FIBRINOGEN WITH ALCOHOLICS 
 
This picture depicts the mean fibrinogen value in both alcoholics and 
non-alcoholics. The relation obtained was not statistically significant. 
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CORRELATION OF MEAN FIBRINOGEN VALUE WITH 
HYPERTENSIVES AND NON HYPERTENSIVES 
 
FIGURE-28 CORRELATION OF MEAN FIBRINOGEN VALUE 
WITH HYPERTENSIVES AND NON HYPERTENSIVES 
The mean fibrinogen was slightly higher among known hypertensives. 
But we could not establish a statistically significant relation between these 
two. 
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FIGURE-29 COMPARISON OF MEAN FIBRINOGEN VALUE WITH 
DIABETES AND NON DIABETES PATIENTS. 
 
 The mean fibrinogen was significantly higher in diabetic patients 
when compared to non-diabetic patients and the increase in value was 
statistically significant. 
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 FIGURE-30 CORRELATION BETWEEN MEAN FIBRINOGEN 
WITH RANDOM BLOOD SUGAR 
 
 
The fibrinogen value at the time of admission was correlated with 
random blood sugar at the time of admission and there was a significant 
correlation between these two variables. 
 
 
0
50
100
150
200
250
300
350
400
450
0 100 200 300 400 500 600
R
an
d
o
m
 B
lo
o
d
 S
u
ga
r 
Fibrinogen 
Random Blood Sugar 
98 
 
 
FIGURE-31 CORRELATION BETWEEN FIBRINOGEN AND SSS 
 
 
This line chart represents that as the fibrinogen value increases the 
SSS score decreases. This scoring assesses the severity of stroke and it was 
found to be statistically significant. 
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FIGURE-32 CORRELATION BETWEEN FIBRINOGEN WITH 
MODIFIED RANKIN SCALE AT THE TIME OF ADMISSION 
 
 
 
     This diagram represents the linear relationship between fibrinogen 
value and Rankin score at the time of admission. This scale represents the 
functional outcome of patients. In our study higher the fibrinogen value 
carries poor functional outcome.  
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Figure-33 CORRELATION BETWEEN FIBRINOGEN WITH 
MODIFIED RANKIN SCALE AT DISCHARGE 
 
 
 
     The admission fibrinogen value correlated with the functional 
outcome of patients with MRS at the time of discharge. Patients having 
higher fibrinogen value at the time of admission has significant disability at 
the time of discharge and the correlation was statistically significant.  
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DISCUSSION 
 
     This study was conducted among the Indian population involving 100 
patients who got admitted in our hospital with clinical features and 
investigations suggestive of cerebrovascular accident. We evaluated history 
regarding smoking, alcoholism known hypertension and diabetes. And also 
we measured blood pressure random blood sugar and other parameters. 
     We calculated the severity of stroke at the time of admission by 
Scandinavian stroke scale and measured the functional outcome of patients 
by modified Rankin scale at the time of admission and discharge. We 
measured plasma fibrinogen in all the patients in our study group. In our 
study no patients were treated with thrombolysis for stroke. 
   Many studies demonstrated that increased level of inflammatory 
markers like IL-6, CRP, fibrinogen following an acute stroke predicts an 
unfavourable outcome among stroke patients. Fibrinogen is one such acute 
phase protein. Cerebral ischemia triggers the acute phase reaction and 
thereby increasing the concentration of fibrinogen value following an acute 
stroke. 
     We evaluated the fibrinogen value with Scandinavian stroke 
scale(ranges from 0-58) and found that the fibrinogen value was inversely 
related with stroke severity and it was found to be statistically significant 
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(p<0.01). The mean SSS scoring was 29.91.Hence patients having high 
fibrinogen value associated with increased severity of stroke.  
Swarowskaet all 
[80]
 conducted a study of about 266 patients admitted 
with stroke. They measured the fibrinogen value at admission 7
th
 and 14th 
day and correlated with the severity and outcome of the patients with NIHSS 
and MRS measured at day 1 and 30
th
 day and found a significant correlation 
between fibrinogen and stroke severity and outcome. 
      Modified Rankin scale ranges from 0-6. The value of 6 indicates the 
patient is dead. Higher value of MRS score indicate poor functional 
outcome. In our study the modified Rankin scale measured at the time of 
admission and discharge correlated well with the fibrinogen value and was 
statistically significant. The mean MRS at the time of admission was 3.96. 
Hence higher the fibrinogen value at the time of admission poorer the 
functional outcome of stroke patients. 
  We proceeded with computing correlation coefficient for these 
parameters and found a higher value for MRS-at the time  of admission( 
correlation coefficient-0.594) and least value with diastolic blood 
pressure(correlation coefficient 0.054) 
     We also tried to correlate between the fibrinogen value with important 
risk factors like smoking, alcohol, systemic hypertension and diabetes. The 
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mean fibrinogen value was increased with smoking systemic hypertension 
and diabetes. The mean fibrinogen was normal in patients who are alcoholic. 
And we could establish a statistically significant relationship only with 
patients having diabetes. 
       In the Scottish heart health study, plasma fibrinogen was measured in 
8824 patients and found a significant fibrinogen elevation in patients with 
premature heart disease, diabetes, hypertension and intermittent claudication. 
 In Framingham study they found a significant correlation between 
smokers and fibrinogen value. The fibrinogen value was elevated in smokers 
as compared to non-smokers and found to be statistically significant.   
    Also we found there was a significant correlation between the random 
blood sugar and diabetes with fibrinogen value depicting the importance of 
underlying atherosclerotic process in diabetes.  
In our study 12 patients were expired during the course of stay in 
hospital and we found that the mean fibrinogen was elevated among the dead 
patients indicating higher values of fibrinogen with worst outcome. 
   The limitation of our study is that we did not measure other 
inflammatory markers associated with acute stroke like IL-6 C-Reactive 
protein. 
 
104 
 
CONCLUSION 
Following conclusion was made from our study. 
1. Plasma fibrinogen level at the time of admission correlated with the 
severity of stroke. This is evidenced by as the plasma fibrinogen value 
increases the Scandinavian stroke scale decreases. 
2. Although the mean fibrinogen value was increased among smokers, 
hypertensive, and diabetes we could not establish a statistically 
significant correlation between fibrinogen and smokers and 
hypertension patients, whereas in diabetics a significant correlation 
was observed. 
3. Plasma fibrinogen acts as a prognostic marker to predict functional 
outcome of stroke. This is evidenced by higher plasma fibrinogen 
values correlated with modified Rankin scale at the time of admission 
and discharge. 
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FUTURE DIRECTIONS 
      Although the fibrinogen as an inflammatory marker, predicts the 
severity and functional outcome in acute stroke, it was still unclear whether 
the elevation is an epiphenomenon to stroke. Hence it is important to 
recognise the mechanisms leading to elevation of this inflammatory marker 
in stroke so that fibrinogen could be a potential therapeutic target.   
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                                    ANNEXURES 
i) PROFORMA 
Name: 
 
Age&Sex 
 
 IP No                            DOA:                        Address;                                    Ph; 
 
Time duration: 
 
 Presenting complaints: 
 
LOC:       Seizures:        Fever:        Others: 
 
     Past History 
 
HTN       DM      PT      BA     IHD        CVA      Seizures  
 
     Personal history 
 
Smoking         Alcoholism 
 
General Examination 
 BP:     pulse    RR         JVP:     Temperature: 
 
CVS 
 
RS 
 
GIT 
 
CNS  
 
 
 
 
INVESTIGATIONS: 
 
CBC: 
 
Blood  
   Sugar:  
   Urea: 
Creatinine:  
   Electrolytes: 
 
Urine 
   Sugar 
   Albumin 
   Deposits 
 
ECG 
 
CXR 
 
Lipid profile 
 
Serum cortisol 
 
CT Brain: 
 
 SSS 
 
1. Consciousness 
 
2. Orientation 
 
3. Speech 
 
 
 
4. Eye movements 
 
5. Facial palsy 
 
6. Gait 
 
7. Arm power 
 
8. Hand power 
 
9. Leg power 
 
ADMISSION  
DISCHARGE  
 
MRS (0-6) 
 
Patient’s outcome : discharged / death  
 
 
 
 
 
 
 
 
 
 
 
 
 
iii) ABBREVATIONS 
 
CRP C-reactive protein 
NIHSS National institute of health stroke scale 
TIA Transient ischemic attack 
RIND Reversible ischemic neurological deficit 
TCD Transcranial Doppler ultrasound 
NMDA N-methyl-D-aspartate 
NOS Nitric oxide synthase 
MMP Matrix metalloprotease 
APOE Apolipoprotein E 
ASA/AHA American stroke association/American heart association 
ICA Internal carotid artery 
CCA Common carotid artery 
ACA Anterior cerebral artery 
PCA Posterior cerebral artery 
ACoA Anterior communicating artery 
PCoA Posterior communicating artery 
SSS Scandinavian stroke scale 
MRS Modified rankin scale 
SBP Systolic blood pressure 
DBP  Diastolic blood pressure 
 
 
 
 
Sl.No NAME
AGE < 
60
AGE > 60 SEX SMOKER ALCOHOLIC SBP DBP SHT DM SUGAR SSS
MRS - 
Admission
MRS - 
Discharge
FIBRINOGEN OUTCOME ISHEMIC HMRG
1 ABBUBAKER 38 M S 150 90 193 11 5 453 DEATH +
2 SUBBURAJ 33 M S S 120 70 280 40 3 2 426 DIS +
3 MURUGAN 40 M S 130 80 146 28 4 2 400 DIS +
4 MUTHU 34 M S S 160 100 S S 163 28 4 2 400 DIS +
5 SUDALAIMUTH 65 M S S 180 100 S S 237 30 3 2 428 DIS +
6 SELVARAJ 80 M S 180 110 S 105 4 5 255 DEATH +
7 SANKARAN 65 M S S 130 70 283 40 3 2 348 DIS +
8 GOMATHY 78 F 110 70 163 34 3 2 232 DIS +
9 NAMBIRAJAN 46 M S S 170 90 S 82 36 3 2 302 DIS +
10 ARUMUGAM 62 M 140 90 S 231 28 4 3 246 DIS +
11 MUTHANU 40 F 150 90 153 28 5 4 360 DIS +
12 MEENATCHI 65 F 180 100 189 18 5 4 440 DIS +
13 SALAPATHY 43 M 130 90 143 36 3 2 192 DIS +
14 SUDALIAMMAL 65 F 170 90 S 183 17 5 455 DEATH +
15 GANAPAMMA 70 F 190 100 S 202 11 5 440 DEATH +
16 SANKARAMMAL 65 F 140 80 S 306 11 5 5 500 DIS +
17 AMBIKAVATHY 65 F 130 90 S 400 26 5 4 474 DIS +
18 MOOKANDI 36 M S 180 90 S 187 27 5 3 402 DIS +
19 PERUMAL 50 M S 200 100 S 180 33 4 2 380 DIS +
20 MURUGESAN 47 M S 130 90 183 12 5 500 DEATH +
21 VASANTH 68 F 130 90 S 180 22 5 3 480 DIS +
22 VASANTH 58 M S 160 90 S 120 36 4 2 450 DIS +
23 RATHINAM 68 F 130 90 S 320 26 5 5 480 DIS +
24 GAAPATHY 55 F 130 70 S 123 14 5 5 500 DIS +
25 PETCHIAMMA 55 F 180 90 S 263 8 5 5 510 DIS +
26 RAJAMANI 65 F 130 80 153 33 4 2 470 DIS +
27 ABDUL AHAB 58 M S 130 70 301 39 4 2 323 DIS +
28 MADASAMY 65 M S 130 80 S 211 34 4 2 420 DIS +
29 ESAKKI 51 M S 140 86 242 41 3 2 179 DIS +
30 RAMACHANDRAN 50 M 130 70 S 383 30 3 2 246 DIS +
31 AVUDAIAMMA 80 F 130 80 280 32 4 2 404 DIS +
32 VADIVU 54 F 160 70 S 211 40 3 2 379 DIS +
33 SUBBAMMAL 65 F 200 100 S 280 4 5 - 420 DEATH +
34 PADMANABAN 65 M S S 120 70 S 390 18 5 5 512 DIS +
35 RAMASAMY 78 M S 130 80 S 283 24 5 5 414 DIS +
36 RAJENDRAN 51 M S 170 90 S 180 16 5 5 463 DIS +
37 KARPAGAM 53 F 130 90 141 35 4 4 430 DIS +
38 SUBBURAJ 48 M 130 70 S 180 24 4 4 460 DIS +
39 GUNASEELAN 55 M 130 60 123 37 4 3 420 DIS +
40 AYYAMMAL 41 F 130 70 200 33 4 2 360 DIS +
41 CHELLIAH 55 M S 160 80 S 103 44 3 2 184 DIS +
42 THANGARAJ 64 M S 160 80 S S 180 42 3 2 420 DIS +
43 KALIAMMAL 55 F 160 80 S 174 42 3 2 425 DIS +
44 ESAKKI 58 M S 130 80 S 302 24 5 5 512 DIS +
45 MARIYA 58 F 120 70 S 356 22 5 5 472 DIS +
46 RAJA 68 M S 130 90 102 30 4 2 350 DIS +
47 ARUMUGAM 85 M 160 100 S 120 41 3 2 382 DIS +
48 SIVA 50 M 130 70 126 30 4 2 357 DIS +
49 MARIAMMAL 31 F 120 80 200 39 3 2 256 DIS +
50 KUMAR 76 M S 140 70 S 210 24 5 4 480 DIS +
51 MARIAMMAL 31 F 160 100 S S 380 12 5 - 530 DEATH +
52 RATHINAMMA 62 F 130 80 S 200 31 4 3 450 DIS +
53 SUBBULAKSHMI 55 F 170 100 S 160 24 5 4 480 DIS +
54 THANGAPANDI 45 M 130 70 S 130 44 3 2 400 DIS +
55 THANGAMMAL 55 F 130 90 S 380 31 4 3 470 DIS +
56 PARAMASIVAN 60 M S 120 70 S 310 10 5 _ 510 DEATH +
57 SYEALIFATHIMA 30 F 120 80 120 44 4 2 350 DIS +
58 THANGAMUTHU 55 M 150 80 S 200 33 4 3 400 DIS +
59 PARVATHI 60 F 170 100 S 120 10 5 5 520 DIS +
60 GANESAN 61 M S S 130 80 S 200 18 5 5 490 DIS +
61 PITCHAMMAL 60 F 130 70 s 250 33 4 2 356 dis +
62 RANGASAMY 50 M s 150 80 s 300 40 3 2 430 dis +
63 POOMARI 75 M 160 80 s s 360 37 3 2 280 dis +
64 JEYAM 60 F 160 100 380 35 3 2 400 dis +
65 MUTHAMMAL 80 F 140 80 s 320 40 3 1 380 dis +
66 SUBBULAKSHMI 53 F 160 90 s 153 30 4 2 426 dis +
67 THANGARASI 62 M 130 90 S 320 28 4 2 430 DIS +
68 DURAI 65 M S S 130 70 S 402 28 5 4 460 DIS +
69 SRIVALLI 56 M S 120 70 126 28 5 5 480 DIS +
70 MAHARAJN 70 M S S 150 90 S 108 42 3 2 380 DIS +
71 MUTHUKRISNAN 50 M S 120 80 228 42 3 2 378 DIS +
72 SUDALIAMMAL 68 F 170 100 S 295 23 5 4 489 DIS +
73 CHELLATHAI 65 F 160 100 S 103 28 4 2 450 DIS +
74 PETCHIAMMAL 48 F 120 80 S 279 26 5 2 472 DIS +
75 PTRATCHI 54 F 180 100 123 38 4 350 DEATH +
76 PITCHAMANI 64 M S 130 80 S 200 42 2 2 360 DIS +
77 KRISHNA 49 M S 160 90 S 110 28 5 5 433 DIS +
78 KANIAMMAL 62 F S 110 70 96 32 4 3 412 DIS +
79 ESAKKIAMMAL 60 F 180 90 s 112 44 2 2 380 DIS +
80 SUBBAMMAL 72 F 120 80 120 40 2 2 400 DIS +
81 MAHARAJAN 55 M S 150 90 132 38 3 2 350 DIS +
82 SAHUL HAMEED 63 M 120 70 130 20 5 5 460 DIS +
83 VINCENT 48 M S 160 100 S 280 28 5 4 490 DIS +
84 GOVIND 53 M S 180 100 S 108 38 2 2 500 DIS +
85 DURAIPANDI 60 M S 130 80 110 40 2 2 210 DIS +
86 KANI 78 F 190 100 S 210 20 5 350 DEATH +
87 RAJAMMA 80 F 180 100 S 134 28 5 512 DEATH +
88 RAGURAM 78 M S 120 70 S 280 34 4 2 480 DIS +
89 KUMARAVEL 66 M S S 140 89 S 245 40 3 2 400 DIS +
90 RAMESH 43 M S 130 70 230 38 3 2 380 DIS +
91 ARAVAN 70 M S S 150 90 189 32 4 3 420 DIS +
92 RAMAN 66 M 130 60 S 270 20 5 5 490 DIS +
93 RAGUPATHY 70 M S 140 70 S 201 40 3 2 289 DIS +
94 PONNAMAL 66 F 130 80 180 42 3 2 360 DIS +
95 SANKARAMMAL 70 F S 120 70 S 120 40 2 2 189 DIS +
96 KUMARAN 50 M 130 70 134 42 2 1 350 DIS +
97 PALANIAMMAL 69 F 120 80 S 230 36 3 2 401 DIS +
98 RASIGAN 59 M S 150 80 S 190 28 4 4 450 DIS +
99 KUMUTHA 66 F 130 80 S 170 38 3 3 428 DIS +
100 SORIMUTHU 70 M S S 150 70 S 189 26 5 500 DEATH +
